AGRX
AGRX Real Time Price USDRecent trades of AGRX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by AGRX's directors and management
Government lobbying spending instances
-
$45,000 Apr 12, 2024 Issue: Health Issues
-
$45,000 Oct 18, 2023 Issue: Health Issues
-
$45,000 Jul 17, 2023 Issue: Health Issues
-
$45,000 Apr 17, 2023 Issue: Health Issues
-
$45,000 Jan 19, 2023 Issue: Health Issues
-
$45,000 Oct 20, 2022 Issue: Health Issues
-
$45,000 Jul 18, 2022 Issue: Health Issues
-
$45,000 Apr 20, 2022 Issue: Health Issues
-
$60,000 Jan 19, 2022 Issue: Health Issues
-
$50,000 Oct 20, 2021 Issue: Health Issues
-
$50,000 Jul 20, 2021 Issue: Health Issues
-
$20,000 Apr 20, 2021 Issue: Health Issues
Estimated quarterly lobbying spending
New patents grants
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of AGRX in WallStreetBets Daily Discussion
Recent insights relating to AGRX
Recent picks made for AGRX stock on CNBC
ETFs with the largest estimated holdings in AGRX
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AGRX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.